Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE: BMS) announced on December 3, 2025 that the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer’s disease will continue with additional patient enrollment after a blinded review identified site-level irregularities.
The company excluded data from the affected sites before database lock, ran an independent interim efficacy and safety analysis with FDA consultation, and the Data Monitoring Committee recommended resuming enrollment to the original target population. BMS remains blinded to study data and expects ADEPT program readouts, including ADEPT-2, by end of 2026.
Bristol Myers Squibb (NYSE: BMY) disclosed more than 95 data disclosures, including 27 oral presentations, at ASH 2025 highlighting advances across multiple myeloma, lymphomas and myeloid diseases.
Key clinical updates include durable responses with CELMoD agents: iberdomide (maintenance and combos) showing sustained MRD negativity in newly diagnosed multiple myeloma, golcadomide with continued efficacy at 24 months in aggressive B-cell lymphoma and extended follow-up in R/R FL and DLBCL, and a first-in-class BCL6 ligand-directed degrader showing encouraging activity in R/R NHL.
Long-term liso-cel (Breyanzi) data show sustained benefit at 3–4 years in FL and LBCL; full safety profiles, including CRS and neurologic event rates, were reported.
Bristol Myers Squibb (NYSE: BMY) will participate in Citi’s 2025 Global Healthcare Conference on Thursday, December 4, 2025. The company will appear in a fireside chat beginning at 9:00 a.m. ET. Investors and the public can listen live via http://investor.bms.com, and an archived edition will be available after the session.
The company reiterated its mission to discover, develop and deliver innovative medicines. Media and investor contact emails are provided for follow-up.
Bristol Myers Squibb (NYSE: BMY) announced that on November 24, 2025 the European Commission approved Breyanzi (lisocabtagene maraleucel) for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior systemic therapies including a BTK inhibitor. Approval covers EU member states and EEA countries Iceland, Norway and Liechtenstein.
Approval is based on TRANSCEND MCL results: overall response rate 82.7%, complete response 71.6%, and 50.8% of patients still in response at 24 months. Safety was consistent with known profile; most CRS and neurologic events occurred early and resolved.
Bristol Myers Squibb (NYSE: BMY) will host a virtual investor event on Thursday, December 11, 2025 following the conclusion of the American Society of Hematology Annual Meeting and Exposition. The webcast begins at 9:00 a.m. ET and will highlight the company’s Hematology development strategy and recent data.
Materials will be available at http://investor.bms.com at the start of the presentation, and a replay will be posted approximately three hours after the event concludes. Company representatives will provide an overview for investors and analysts.
Bristol Myers Squibb (NYSE: BMY) announced accepted amounts and pricing for its previously announced tender offers for multiple series of outstanding notes. Bristol Myers Squibb set the Amended Pool 1 Maximum at approximately $3.99 billion and the Amended Pool 2 Maximum at approximately $3.51 billion. All Pool 1 Notes and Pool 2 Notes with acceptance priority levels 1–4 tendered by the Early Tender Deadline were accepted in full; the company accepted $250,000,000 of 5.900% 2033 Notes on a prorated basis (approx. 50.84% proration).
The Early Settlement Date is November 20, 2025, and accepted Notes will be cancelled and retired.
Bristol Myers Squibb (NYSE: BMY) reported early participation results for its tender offers as of 5:00 p.m. on November 17, 2025.
The company amended Pool 1 and Pool 2 maximums: Pool 1 maximum decreased to accept all Pool 1 Notes validly tendered; Pool 2 maximum increased to accept all Pool 2 Notes with acceptance priority 1–4 and up to $250,000,000 of 5.900% Notes due 2033. The Early Settlement Date is November 20, 2025; Offers expire on December 3, 2025 if not earlier terminated.
Principal amounts tendered by series are listed and Bristol Myers Squibb expects no final settlement or additional acceptances after the Early Tender Deadline.
Bristol Myers Squibb (NYSE:BMY) and Johnson & Johnson announced discontinuation of the Phase 3 Librexia ACS trial after an Independent Data Monitoring Committee (IDMC) preplanned interim analysis determined the study is unlikely to meet its primary efficacy endpoint.
No new safety concerns were identified and the safety profile remained consistent with prior milvexian studies. The IDMC recommended that the other Phase 3 studies in the Librexia program—Librexia AF and Librexia STROKE—continue as planned, with topline data expected in 2026.
Sarah Cannon Research Institute and Bristol Myers Squibb (NYSE: BMY) expanded a strategic collaboration to accelerate oncology clinical trial enrollment and broaden access to trials in U.S. communities. The partnership centers on SCRI’s Accelero delivery model across 200+ locations and 1,300 physicians in 20+ states to embed BMY trials in community settings.
Early results cited a 45% reduction in study startup timelines across eight BMY trials at SCRI sites versus non-SCRI sites, with the collaboration emphasizing data-driven enrollment, equity, and faster patient access to investigational cancer therapies.
Bristol Myers Squibb (NYSE: BMY) priced a public offering of senior unsecured notes totaling €5.0 billion across five tranches with maturities from 2030 to 2055 and coupons ranging from 2.973% to 4.581%. The notes will be issued by BMS Ireland Capital Funding DAC and fully guaranteed on a senior unsecured basis by Bristol-Myers Squibb Company.
The company expects closing on November 10, 2025, subject to customary conditions. Net proceeds, together with approximately $3.0 billion of cash on hand, are intended to fund a tender offer and other repurchases/repayments, pay fees and expenses, and, if any remains, for general corporate purposes.